Table 4.
Summary of adverse events on rituximab use in nephrotic syndrome from prospective studies
| Study/Author | Study Design | No. of Patients Analyzed | No. of Rituximab Courses | Rituximab Regimen per Course, mg/m2 | Any Side Effects | Serious Side Effects | Infusion Reaction | Neutropenia | Infection | Death | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rituximab | Control | Rituximab | Control | Rituximab | Control | Rituximab | Control | Rituximab | Control | Rituximab | Control | |||||
| Magnasco et al.,30 2012 | RCT | 31 | 16 | 750 | 11 | NR | 2 | NR | 11 | — | NR | NR | NR | NR | 0 | 0 |
| Iijima et al.,5 2014 | DBRCT | 48 | 24 | 1500 | 357 | 251 | 16 | 7 | 41 | 26 | 4 | 0 | 105 | 42 | 0 | 0 |
| Ruggenenti et al.,7 2014 | Off-on trial | 30 | 30 | 375–750 | 8 | — | NR | NR | 0 | — | NR | — | 5 | — | 0 | — |
| Ravani et al.,6 2015 | RCT | 30 | 15 | 375 | NR | NR | 0 | 0 | 15 | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Ahn et al.,31 2018 | RCT | 54 | 36 | 375–750 | 92 | 28 | 3 | 1 | 36 | — | NR | NR | 21 | 4 | 0 | 0 |
| Basu et al.,32 2018 | RCT | 120 | 60 | 750 | 123 | 145 | 7 | 4 | 23 | — | NR | NR | 13 | 26 | 0 | 0 |
| Kari et al.,37 2020 | Prospective cohort | 46 | 19 | 750 | 1 | 7 | NR | NR | 1 | — | 0 | 6 | NR | NR | 0 | 0 |
| Ravani et al.,33 2021 | RCT | 30 | 15 | 375 | NR | NR | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Ravani et al.,16 2021 | RCT | 140 | 70 | 750 | 11 | 5 | 0 | 0 | 7 | 4 | 2 | 1 | NR | NR | 0 | 0 |
| Mathew et al.,34 2022 | RCT | 40 | 20 | 750 | 133 | 181 | 1 | 4 | 12 | — | 1 | 0 | 86 | 67 | 0 | 0 |
| Total | 569 | 305 | — | 736/275 | 617/219 | 29/256 | 16/222 | 146/305 | 30/94 | 7/163 | 7/171 | 230/200 | 139/152 | 0/305 | 0/264 | |
| Episode per rituximab course | 2.67 | 2.81 | 0.11 | 0.07 | 0.47 | 0.32 | 0.04 | 0.04 | 1.15 | 0.91 | 0 | 0 | ||||
RCT, randomized controlled trial; NR, not reported; DBRCT, double-blind randomized placebo-controlled trial.